Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 11

1.

Advanced solid tumors treated with cediranib: comparison of dynamic contrast-enhanced MR imaging and CT as markers of vascular activity.

Messiou C, Orton M, Ang JE, Collins DJ, Morgan VA, Mears D, Castellano I, Papadatos-Pastos D, Brunetto A, Tunariu N, Mann H, Tessier J, Young H, Ghiorghiu D, Marley S, Kaye SB, deBono JS, Leach MO, deSouza NM.

Radiology. 2012 Nov;265(2):426-36. doi: 10.1148/radiol.12112565. Epub 2012 Aug 13.

PMID:
22891356
2.

Two-stage phase I dose-escalation study of intratumoral reovirus type 3 dearing and palliative radiotherapy in patients with advanced cancers.

Harrington KJ, Karapanagiotou EM, Roulstone V, Twigger KR, White CL, Vidal L, Beirne D, Prestwich R, Newbold K, Ahmed M, Thway K, Nutting CM, Coffey M, Harris D, Vile RG, Pandha HS, Debono JS, Melcher AA.

Clin Cancer Res. 2010 Jun 1;16(11):3067-77. doi: 10.1158/1078-0432.CCR-10-0054. Epub 2010 May 18.

3.

Quantifying sclerotic bone metastases with 2D ultra short TE MRI: a feasibility study.

Messiou C, Collins DJ, Morgan VA, Robson MD, deBono JS, Bydder GM, deSouza NM.

Cancer Biomark. 2010;7(4):211-8. doi: 10.3233/CBM-2010-0189.

PMID:
21576814
4.

Phase I safety, pharmacokinetic, and pharmacogenomic trial of ES-285, a novel marine cytotoxic agent, administered to adult patients with advanced solid tumors.

Baird RD, Kitzen J, Clarke PA, Planting A, Reade S, Reid A, Welsh L, López Lázaro L, de las Heras B, Judson IR, Kaye SB, Eskens F, Workman P, deBono JS, Verweij J.

Mol Cancer Ther. 2009 Jun;8(6):1430-7. doi: 10.1158/1535-7163.MCT-08-1167. Epub 2009 Jun 9.

5.

Phase I and pharmacokinetic study of XRP6258 (RPR 116258A), a novel taxane, administered as a 1-hour infusion every 3 weeks in patients with advanced solid tumors.

Mita AC, Denis LJ, Rowinsky EK, Debono JS, Goetz AD, Ochoa L, Forouzesh B, Beeram M, Patnaik A, Molpus K, Semiond D, Besenval M, Tolcher AW.

Clin Cancer Res. 2009 Jan 15;15(2):723-30. doi: 10.1158/1078-0432.CCR-08-0596.

6.

Reovirus therapy in cancer: has the orphan virus found a home?

Yap TA, Brunetto A, Pandha H, Harrington K, Debono JS.

Expert Opin Investig Drugs. 2008 Dec;17(12):1925-35. doi: 10.1517/13543780802533401 . Review.

PMID:
19012507
7.

A phase I study of intravenous oncolytic reovirus type 3 Dearing in patients with advanced cancer.

Vidal L, Pandha HS, Yap TA, White CL, Twigger K, Vile RG, Melcher A, Coffey M, Harrington KJ, DeBono JS.

Clin Cancer Res. 2008 Nov 1;14(21):7127-37. doi: 10.1158/1078-0432.CCR-08-0524.

8.

A phase 1 pharmacokinetic and pharmacodynamic study of the histone deacetylase inhibitor belinostat in patients with advanced solid tumors.

Steele NL, Plumb JA, Vidal L, Tjørnelund J, Knoblauch P, Rasmussen A, Ooi CE, Buhl-Jensen P, Brown R, Evans TR, DeBono JS.

Clin Cancer Res. 2008 Feb 1;14(3):804-10. doi: 10.1158/1078-0432.CCR-07-1786.

9.

Phase I and pharmacokinetic study of tasidotin hydrochloride (ILX651), a third-generation dolastatin-15 analogue, administered weekly for 3 weeks every 28 days in patients with advanced solid tumors.

Mita AC, Hammond LA, Bonate PL, Weiss G, McCreery H, Syed S, Garrison M, Chu QS, DeBono JS, Jones CB, Weitman S, Rowinsky EK.

Clin Cancer Res. 2006 Sep 1;12(17):5207-15.

10.

A survey of exercise testing practice in Scottish hospitals.

Muir KW, Rodger JC, DeBono JS, McDonald H, Irving JB.

Scott Med J. 1993 Apr;38(2):45-7.

PMID:
8502977
11.

Drugs and the exercise test.

Muir KW, Rodger JC, DeBono JS, McDonald H, Irving JB.

BMJ. 1992 Oct 3;305(6857):808-9. No abstract available.

Supplemental Content

Loading ...
Support Center